Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-31truetruetrue2023-01-01falseNo description of principal activity1814truefalse 10989365 2023-01-01 2023-12-31 10989365 2022-01-01 2022-12-31 10989365 2023-12-31 10989365 2022-12-31 10989365 2022-01-01 10989365 1 2023-01-01 2023-12-31 10989365 d:CompanySecretary1 2023-01-01 2023-12-31 10989365 d:Director1 2023-01-01 2023-12-31 10989365 d:Director2 2023-01-01 2023-12-31 10989365 d:Director3 2023-01-01 2023-12-31 10989365 d:Director4 2023-01-01 2023-12-31 10989365 d:Director5 2023-01-01 2023-12-31 10989365 d:Director6 2023-01-01 2023-12-31 10989365 d:Director7 2023-01-01 2023-12-31 10989365 d:Director8 2023-01-01 2023-12-31 10989365 d:Director9 2023-01-01 2023-12-31 10989365 d:Director10 2023-01-01 2023-12-31 10989365 d:RegisteredOffice 2023-01-01 2023-12-31 10989365 c:OfficeEquipment 2023-01-01 2023-12-31 10989365 c:OfficeEquipment 2023-12-31 10989365 c:OfficeEquipment 2022-12-31 10989365 c:OfficeEquipment c:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 10989365 c:ComputerEquipment 2023-01-01 2023-12-31 10989365 c:ComputerEquipment 2023-12-31 10989365 c:ComputerEquipment 2022-12-31 10989365 c:ComputerEquipment c:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 10989365 c:OtherPropertyPlantEquipment 2023-01-01 2023-12-31 10989365 c:OtherPropertyPlantEquipment 2023-12-31 10989365 c:OtherPropertyPlantEquipment 2022-12-31 10989365 c:OtherPropertyPlantEquipment c:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 10989365 c:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 10989365 c:CurrentFinancialInstruments 2023-12-31 10989365 c:CurrentFinancialInstruments 2022-12-31 10989365 c:CurrentFinancialInstruments c:WithinOneYear 2023-12-31 10989365 c:CurrentFinancialInstruments c:WithinOneYear 2022-12-31 10989365 c:ShareCapital 2023-01-01 2023-12-31 10989365 c:ShareCapital 2023-12-31 10989365 c:ShareCapital 2022-01-01 2022-12-31 10989365 c:ShareCapital 2022-12-31 10989365 c:ShareCapital 2022-01-01 10989365 c:SharePremium 2023-01-01 2023-12-31 10989365 c:SharePremium 2023-12-31 10989365 c:SharePremium 2022-01-01 2022-12-31 10989365 c:SharePremium 2022-12-31 10989365 c:SharePremium 2022-01-01 10989365 c:CapitalRedemptionReserve 2023-12-31 10989365 c:CapitalRedemptionReserve 2022-12-31 10989365 c:CapitalRedemptionReserve 2022-01-01 10989365 c:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 10989365 c:RetainedEarningsAccumulatedLosses 2023-12-31 10989365 c:RetainedEarningsAccumulatedLosses 2022-01-01 2022-12-31 10989365 c:RetainedEarningsAccumulatedLosses 2022-12-31 10989365 c:RetainedEarningsAccumulatedLosses 2022-01-01 10989365 d:OrdinaryShareClass1 2023-01-01 2023-12-31 10989365 d:OrdinaryShareClass1 2023-12-31 10989365 d:OrdinaryShareClass1 2022-12-31 10989365 d:OrdinaryShareClass2 2023-01-01 2023-12-31 10989365 d:OrdinaryShareClass2 2023-12-31 10989365 d:OrdinaryShareClass2 2022-12-31 10989365 d:OrdinaryShareClass3 2023-01-01 2023-12-31 10989365 d:OrdinaryShareClass3 2023-12-31 10989365 d:OrdinaryShareClass3 2022-12-31 10989365 d:OrdinaryShareClass4 2023-01-01 2023-12-31 10989365 d:OrdinaryShareClass4 2023-12-31 10989365 d:OrdinaryShareClass4 2022-12-31 10989365 d:OrdinaryShareClass5 2023-01-01 2023-12-31 10989365 d:OrdinaryShareClass5 2023-12-31 10989365 d:OrdinaryShareClass5 2022-12-31 10989365 d:FRS102 2023-01-01 2023-12-31 10989365 d:Audited 2023-01-01 2023-12-31 10989365 d:FullAccounts 2023-01-01 2023-12-31 10989365 d:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 10989365 d:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 10989365 2 2023-01-01 2023-12-31 10989365 6 2023-01-01 2023-12-31 10989365 7 2023-01-01 2023-12-31 10989365 e:PoundSterling 2023-01-01 2023-12-31 xbrli:shares iso4217:GBP xbrli:pure


Registered number: 10989365












GREY WOLF THERAPEUTICS LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

 

GREY WOLF THERAPEUTICS LIMITED

CONTENTS



Page
Company information
 
1
Balance sheet
 
2
Statement of changes in equity
 
3
Notes to the financial statements
 
4 - 13


 

GREY WOLF THERAPEUTICS LIMITED
 
COMPANY INFORMATION


Directors
Dr P Joyce 
Mr B K Ahrens 
Dr T D McCarthy 
Dr T Hercend 
Mr R Wisniewski 
Dr S M Dewhurst 
Ms E Johnson 
Ms R Nasrallah 
Ms M C Peakman 
Ms T Weightman 




Company secretary
S A Harris



Registered number
10989365



Registered office
99 Park Drive
Milton

Abingdon

OX14 4RY




Independent auditor
Blick Rothenberg Audit LLP
Chartered Accountants & Statutory Auditor

16 Great Queen Street

Covent Garden

London

WC2B 5AH




Page 1


 
REGISTERED NUMBER:10989365
GREY WOLF THERAPEUTICS LIMITED

BALANCE SHEET
AS AT 31 DECEMBER 2023

2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 4 
57,111
77,503

Investments
 5 
5
5

  
57,116
77,508

Current assets
  

Debtors: amounts falling due within one year
 6 
6,606,933
1,413,201

Cash at bank and in hand
  
9,031,259
9,568,847

  
15,638,192
10,982,048

Creditors: amounts falling due within one year
 7 
(2,329,021)
(928,661)

Net current assets
  
 
 
13,309,171
 
 
10,053,387

Net assets
  
13,366,287
10,130,895


Capital and reserves
  

Called up share capital 
 8 
1,557
1,092

Share premium account
  
52,225,802
33,086,571

Capital redemption reserve
  
3
3

Profit and loss account
  
(38,861,075)
(22,956,771)

Total equity
  
13,366,287
10,130,895


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Dr T D McCarthy
Director

Date: 19 August 2024

The notes on pages 4 to 13 form part of these financial statements.

Page 2

 

GREY WOLF THERAPEUTICS LIMITED

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2023


Called up share capital
Share premium account
Capital redemption reserve
Profit and loss account
Total equity

£
£
£
£
£


At 1 January 2022
843
22,959,179
2
(16,806,522)
6,153,502



Loss for the year
-
-
-
(6,150,248)
(6,150,248)

Purchase of own shares
-
-
1
(1)
-

Shares issued during the year
250
10,127,392
-
-
10,127,642

Shares cancelled during the year
(1)
-
-
-
(1)



At 31 December 2022 and 1 January 2023
1,092
33,086,571
3
(22,956,771)
10,130,895



Loss for the year
-
-
-
(15,904,304)
(15,904,304)

Shares issued during the year
465
19,139,231
-
-
19,139,696


At 31 December 2023
1,557
52,225,802
3
(38,861,075)
13,366,287


The notes on pages 4 to 13 form part of these financial statements.

Page 3

 

GREY WOLF THERAPEUTICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1.


General information

Grey Wolf Therapeutics Limited is a private company limited by shares incorporated in England and Wales. The address of its registered office is 99 Park Drive, Milton, Abingdon, England, OX14 4RY.
The financial statements are presented in Sterling (£), which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Exemption from preparing consolidated financial statements

The company, and the group headed by it, qualify as small as set out in section 383 of the Companies Act 2006 and the parent and group are considered eligible for the exemption to prepare consolidated accounts.

The financial statements present information about the company as an individual entity and not about it's group.

 
2.3

Going concern

Losses will continue to be generated in the year to 31 December 2024 as the company is in its research and development phase and operating in line with its business plan.
The company has carried out recent fundraising exercises to provide additional capital for the company. This includes a $40.9 million of new equity issued and settled in April and May 2024, with further tranches expected in 2025.  
The directors have prepared budgets and cashflow forecasts with a worst-case scenario based on contractually committed expenditure. The directors estimate that the cash held by the company together with known receivables will be sufficient to support the current level of activities.
The directors therefore have a reasonable expectation that the company will have adequate resources to continue in operational existence and meet its liabilities as they fall due for the foreseeable future, being a period of at least twelve months from the date of approval of these financial statements. Accordingly, the financial statements have been prepared on a going concern basis.

Page 4

 

GREY WOLF THERAPEUTICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.4

Foreign currency translation

Functional and presentation currency

The company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Profit and loss account within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

 
2.5

Turnover

Grants of a revenue nature are recognised in the profit and loss account in the same period as the related expenditure. The deferred element of grants is included in creditors as deferred income.

 
2.6

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

The company is currently in the research phase of its project and all such expenditure has been recognised in the Profit and loss account.

 
2.7

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Profit and loss account in the same period as the related expenditure.

Page 5

 

GREY WOLF THERAPEUTICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.8

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.9

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.10

Pensions

Defined contribution pension plan

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the company in independently administered funds.

 
2.11

Share-based payments

Where share options are awarded to employees, the fair value of the options at the date of grant is charged to profit or loss over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each balance sheet date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options granted. The cumulative expense is not adjusted for failure to achieve a market vesting condition.
The fair value of the award also takes into account non-vesting conditions. These are either factors beyond the control of either party (such as a target based on an index) or factors which are within the control of one or other of the parties (such as the company keeping the scheme open or the employee maintaining any contributions required by the scheme).
Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period.
Where equity instruments are granted to persons other than employees, profit or loss is charged with fair value of goods and services received.

 
2.12

Taxation

The tax expense for the year comprises current tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.
Current tax is the amount of income tax payable in respect of taxable profit for the year or prior years.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income.

Page 6

 

GREY WOLF THERAPEUTICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.13

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

The estimated useful lives range as follows:

Office equipment
-
4
years
Computer equipment
-
3
years
Leasehold improvements
-
4
years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.14

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.15

Cash at bank

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

 
2.16

Holiday pay accrual

A liability is recognised to the extent of any unused holiday pay entitlement which is accrued at the balance sheet date and carried forward to future periods. This is measured at the undiscounted salary cost of the future holiday entitlement so accrued at the balance sheet date.

  
2.17

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Page 7

 

GREY WOLF THERAPEUTICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)


2.18

Financial instruments

The company has elected to apply Sections 11 and 12 of FRS 102 in respect of financial instruments.

Financial assets and financial liabilities are recognised when the company becomes party to the contractual provisions of the instrument. 

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. 
 
The company’s policies for its major classes of financial assets and financial liabilities are set out below. 

Financial assets
Basic financial assets, including trade and other debtors, cash and bank balances, intercompany working capital balances, and intercompany financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

Financial liabilities

Basic financial liabilities, including trade and other creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Page 8

 

GREY WOLF THERAPEUTICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)




Financial instruments (continued)

Impairment of financial assets
Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account. 

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the company would receive for the asset if it were to be sold at the reporting date. 

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets and financial liabilities
Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions. 
 
Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Offsetting of financial assets and financial liabilities
Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.


3.


Employees

The average monthly number of employees, including directors, during the year was 18 (2022 - 14).

Page 9

 

GREY WOLF THERAPEUTICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

4.


Tangible fixed assets





Office equipment
Computer equipment
Other fixed assets
Total

£
£
£
£



Cost


At 1 January 2023
45,623
24,255
77,556
147,434


Additions
3,180
22,244
-
25,424



At 31 December 2023

48,803
46,499
77,556
172,858



Depreciation


At 1 January 2023
21,005
15,496
33,430
69,931


Charge for the year
13,424
10,958
21,434
45,816



At 31 December 2023

34,429
26,454
54,864
115,747



Net book value



At 31 December 2023
14,374
20,045
22,692
57,111



At 31 December 2022
24,618
8,759
44,126
77,503

Page 10

 

GREY WOLF THERAPEUTICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

5.


Fixed asset investments





Investments in subsidiary companies

£



Cost


At 1 January 2023
5



At 31 December 2023
5





6.


Debtors

2023
2022
£
£

Amounts owed by group undertakings
424,990
42,582

Other debtors
3,923,864
228,787

Prepayments and accrued income
197,231
89,420

Tax recoverable
2,060,848
1,052,412

6,606,933
1,413,201


Amounts owed by group undertakings are unsecured, interest free and repayable on demand.


7.


Creditors: Amounts falling due within one year

2023
2022
£
£

Trade creditors
1,337,066
650,530

Other taxation and social security
268,684
62,253

Other creditors
7,049
473

Accruals and deferred income
716,222
215,405

2,329,021
928,661


Page 11

 

GREY WOLF THERAPEUTICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

8.


Share capital

2023
2022
£
£
Allotted, called up and fully paid



1,688,528 (2022 - 1,687,061) Ordinary shares of £0.0001 each
169
169
3,597,122 (2022 - 3,597,122) Series A1 Preferred shares of £0.0001 each
360
360
691,755 (2022 - 691,755) Series A2 Preferred shares of £0.0001 each
69
69
2,454,223 (2022 - 2,454,223) Series A3 Preferred shares of £0.0001 each
245
245
7,137,113 (2022 -2,486,587) Series B Preferred shares of £0.0001 each
714
249

1,557

1,092


The company issued share capital includes 355,195 (2022: 353,728) Ordinary £0.0001 shares which are subject to buyback provisions. 
In January 2023, 4,650,526 Series B Preferred £0.0001 shares were issued at £4.1561 per share. Total consideration was £19,328,051 and the premium of £19,327,585 has been credited to the share premium account.
The preferred shares have certain priority rights in respect of dividends or liquidation as noted in the Articles and Memorandum of Association. All ordinary and preferred shares have equal voting rights.


9.


Pension commitments

The company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £46,929 (2022: £16,612). Contributions totaling £7,049 (2022: £473) were payable to the fund at the balance sheet date and are included in creditors.


10.Other financial commitments

At the balance sheet date, the company had commitments totaling £5,613,688 (2022: £1,933,253) relating to the uninvoiced cost of future research activities contractually agreed with suppliers.


11.


Share options

As at 31 December 2023 there was a total of 124,283 (2022: 127,638) EMI share options in issue.

Page 12

 

GREY WOLF THERAPEUTICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

12.


Related party transactions

The company has taken advantage of the exemptions available under FRS 102 to not disclose transactions with 100% owned group companies.
At the balance sheet date, the balance with the company's subsidiary can be seen in the debtor/creditor note above.
During the year, a company with a common director invoiced the company £4,721,458 (2022: £1,828,273) for services provided and paid invoices on behalf of the company of £6,757 (2022: £2,374). The company paid invoices from the company with a common director totaling £4,603,674 (2022: £1,502,471) during the year. At the year end, the company owed a company with a common director £434,456 (2022: £323,428).


13.


Post balance sheet events

On 7 February 2024 the company issued 13,185 Ordinary shares at £1.25 per share.
On 8 March 2024 the company issued 4,680 Ordinary shares at £1.25 per share.
On 5 April 2024 the company issued 3,432,665 Series B Preferred shares at £4.1561 per share.
On 22 May 2024 the company issued 4,914,958 Series B2 Preferred shares at £4.061 per share.


14.


Auditor's information

The auditor's report on the financial statements for the year ended 31 December 2023 was unqualified.

The audit report was signed on 23 August 2024 by Mahmood Ramji (Senior statutory auditor) on behalf of Blick Rothenberg Audit LLP.

 
Page 13